JP2022509257A - ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 - Google Patents

２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 Download PDF

Info

Publication number
JP2022509257A
JP2022509257A JP2021530883A JP2021530883A JP2022509257A JP 2022509257 A JP2022509257 A JP 2022509257A JP 2021530883 A JP2021530883 A JP 2021530883A JP 2021530883 A JP2021530883 A JP 2021530883A JP 2022509257 A JP2022509257 A JP 2022509257A
Authority
JP
Japan
Prior art keywords
leukemia
cancer
compound
flt3
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509257A5 (https=
Inventor
ウィリアム ライス，
Original Assignee
アプトース バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプトース バイオサイエンシズ インコーポレイテッド filed Critical アプトース バイオサイエンシズ インコーポレイテッド
Publication of JP2022509257A publication Critical patent/JP2022509257A/ja
Publication of JP2022509257A5 publication Critical patent/JP2022509257A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021530883A 2018-11-30 2019-12-02 ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 Pending JP2022509257A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773686P 2018-11-30 2018-11-30
US62/773,686 2018-11-30
PCT/US2019/063993 WO2020113216A1 (en) 2018-11-30 2019-12-02 Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations

Publications (2)

Publication Number Publication Date
JP2022509257A true JP2022509257A (ja) 2022-01-20
JP2022509257A5 JP2022509257A5 (https=) 2022-12-14

Family

ID=70849819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530883A Pending JP2022509257A (ja) 2018-11-30 2019-12-02 ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法

Country Status (8)

Country Link
US (1) US20200171001A1 (https=)
EP (1) EP3886840A4 (https=)
JP (1) JP2022509257A (https=)
KR (1) KR20210150353A (https=)
CN (1) CN113365622A (https=)
AU (1) AU2019387508A1 (https=)
CA (1) CA3133376A1 (https=)
WO (1) WO2020113216A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PY2125608A (es) * 2020-04-01 2021-12-28 Fmc Corp Atropisómeros de derivados de piridazinona como herbicidas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160312311A1 (en) * 2013-03-12 2016-10-27 Novartis Ag Markers for isocitrate dehydrogenase inhibitors
WO2017117372A1 (en) * 2015-12-30 2017-07-06 Agios Pharmaceuticals, Inc. Treatment of tumors incorporating mutant isocitrate dehydrogenase
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2018156578A1 (en) * 2017-02-21 2018-08-30 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
CN108883184A (zh) * 2015-12-04 2018-11-23 安吉奥斯医药品有限公司 治疗恶性肿瘤的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
DK2940014T3 (en) * 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
CA3029851A1 (en) * 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160312311A1 (en) * 2013-03-12 2016-10-27 Novartis Ag Markers for isocitrate dehydrogenase inhibitors
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
CN108883184A (zh) * 2015-12-04 2018-11-23 安吉奥斯医药品有限公司 治疗恶性肿瘤的方法
WO2017117372A1 (en) * 2015-12-30 2017-07-06 Agios Pharmaceuticals, Inc. Treatment of tumors incorporating mutant isocitrate dehydrogenase
WO2018156578A1 (en) * 2017-02-21 2018-08-30 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies

Also Published As

Publication number Publication date
WO2020113216A1 (en) 2020-06-04
EP3886840A4 (en) 2022-08-24
EP3886840A1 (en) 2021-10-06
US20200171001A1 (en) 2020-06-04
CN113365622A (zh) 2021-09-07
CA3133376A1 (en) 2020-06-04
AU2019387508A1 (en) 2021-06-10
KR20210150353A (ko) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7431309B2 (ja) 血液悪性腫瘍患者の治療方法
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
US10106538B2 (en) Inhibitors of protein kinases
TW202136252A (zh) 化合物及其用途
US20180325901A1 (en) Chiral diaryl macrocycles and uses thereof
AU2015271692B2 (en) Benzimidazole analogues and related methods
TW201306842A (zh) 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN103648500B (zh) 双功能酶制钳型分子的方法和用途
US20210246120A1 (en) Method of preparation and use of phosphoinositide 3-kinase inhibitors in treating cancer
JP2022509257A (ja) ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法
JP2019526617A (ja) 治療用化合物
US12258315B2 (en) S6K1 protein kinase inhibitors as cancer therapeutics
WO2015009882A2 (en) Cyano derivatives and their uses
HK40014760A (en) Methods for treating patients with hematologic malignancies
TW202200581A (zh) Ｓｉｋ—３抑制劑及其用途
WO2021032128A1 (zh) 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途
CN108349882A (zh) 一种取代的丙烯酰胺化合物及其药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625